share_log

Virpax Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Virpax Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Virpax制药 | S-1/A：证券上市注册声明(修正)
美股SEC公告 ·  08/13 09:07

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on August 13, 2024. The company is offering up to 6,422,018 shares of common stock and an equal number of pre-funded warrants to purchase common stock. The offering is being conducted on a best-efforts basis by RBW Capital Partners LLC, acting through Dominari Securities LLC, as the sole placement agent. The offering is expected to close one business day after commencement, with the securities delivered upon receipt of investor funds. Virpax intends to use the net proceeds for the development of its product candidate Probudur, working capital, and other general corporate purposes. The company's...Show More
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on August 13, 2024. The company is offering up to 6,422,018 shares of common stock and an equal number of pre-funded warrants to purchase common stock. The offering is being conducted on a best-efforts basis by RBW Capital Partners LLC, acting through Dominari Securities LLC, as the sole placement agent. The offering is expected to close one business day after commencement, with the securities delivered upon receipt of investor funds. Virpax intends to use the net proceeds for the development of its product candidate Probudur, working capital, and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'. The announcement also details the company's recent developments, including a settlement agreement with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc., compliance with Nasdaq's Minimum Stockholders' Equity Rule, and positive results from a Swine Model pilot study for Probudur.
Virpax Pharmaceuticals，Inc.（Virpax）是一家处于临床前阶段的制药公司，于2024年8月13日向证券交易委员会（SEC）提交了S-1表格注册声明的修正案。公司最多提供6，422，018股普通股和等量的预先担保股票购买权证券。该发行是通过RBW Capital Partners LLC进行最大努力的开展，Dominari Securities LLC作为唯一的配售代理。发行有望在启动后一个工作日结束，证券交割取决于投资者资金的收到。Virpax打算将净收益用于产品候选Probudur的开发，营运资金和其他一般企业用途。该公司的普通股在纳斯达克资本市场上挂牌交易，股票代号为“VRPX”。公告还详细介绍了公司的最新进展，包括与Sorrento Therapeutics，Inc.和Scilex Pharmaceuticals Inc.的和解协议，符合纳斯达克股东最低股本规则以及Probudur的猪模型试验的积极结果。
Virpax Pharmaceuticals，Inc.（Virpax）是一家处于临床前阶段的制药公司，于2024年8月13日向证券交易委员会（SEC）提交了S-1表格注册声明的修正案。公司最多提供6，422，018股普通股和等量的预先担保股票购买权证券。该发行是通过RBW Capital Partners LLC进行最大努力的开展，Dominari Securities LLC作为唯一的配售代理。发行有望在启动后一个工作日结束，证券交割取决于投资者资金的收到。Virpax打算将净收益用于产品候选Probudur的开发，营运资金和其他一般企业用途。该公司的普通股在纳斯达克资本市场上挂牌交易，股票代号为“VRPX”。公告还详细介绍了公司的最新进展，包括与Sorrento Therapeutics，Inc.和Scilex Pharmaceuticals Inc.的和解协议，符合纳斯达克股东最低股本规则以及Probudur的猪模型试验的积极结果。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间